Meridian Bioscience Receives Additional NIH Award to Support the Rapid Development of the Revogene® Molecular Viral Respiratory Testing Panel
CINCINNATI, Jan. 31, 2022 /PRNewswire/ — Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today that it has been awarded additional funding in the amount of $2.5M by the National Institute of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) initiative. This award expands the scope of the original $5.5M award to […]